Cell Therapeutics acquires Biogen's Zevalin cancer drug for up to 30 mln usd |
|
|
|
Published
:
Thu, 16 Aug 2007 06:07
|
WASHINGTON Thomson Financial - Biotech firm Cell Therapeutics Inc said it will pay Biogen Idec Inc. up to $30 million for a lymphoma cancer treatment.Seattle-based Cell Therapeutics will take over sales, marketing and development of Zevalin in the U.S., while Bayer Schering will continue to sell the drug outside the country. Zevalin posted sales of $15.4 million in the U.S. last year as a treatment for patients with relapsed non-Hodgkin's lymphoma.Cell Therapeutics management hopes to expand the drug's use to serve an initial treatment for non-Hodgkin's lymphoma.'We see potential for substantial revenue growth for this product,' Cell Therapeutics Chief Executive James Bianco said in a statement.Upon terms of the agreement, Cell Therapeutics will pay Biogen $10 million in cash and up to $20 million in milestone payments when the product receives approval for an additional use. The company plans to hold a news conference Thursday morning to provide details.Shares of Cell Therapeutics fell 12 cents, or 3.3 percent, to $3.47 on Wednesday.Copyright 2007 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.tf.TFN-Europe_newsdesk@thomson.comjlwCOPYRIGHTCopyright AFX News Limited 2007. All rights reserved.The copying, republication or redistribution of AFX News Content, including by framing or similar means, is expressly prohibited without the prior written consent of AFX News.
|
|
|
|
Print this Story
Roche's Genentech issues Avastin warning after fatality in clinical study UPDATE 